Stockscreener 앱 받기
167.34
3.00%
4.87
시간 외 거래:
167.34
전일 마감가:
$162.47
열려 있는:
$162.9
하루 거래량:
200.01K
Relative Volume:
0.94
시가총액:
$6.28B
수익:
-
순이익/손실:
$-32.61M
주가수익비율:
-142.51
EPS:
-1.1742
순현금흐름:
-
1주 성능:
+4.58%
1개월 성능:
+8.01%
6개월 성능:
+168.86%
1년 성능:
+191.89%
1일 변동 폭
$162.82
$171.00
1주일 범위
$155.00
$174.78
52주 변동 폭
$49.00
$174.78
Belite Bio Inc Adr Stock (BLTE) Company Profile
BLTE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
167.34 | 6.10B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 개시 | BofA Securities | Buy |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-02 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 개시 | Mizuho | Neutral |
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
모두보기
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio completes enrollment in phase 2/3 STGD1 drug trial - Investing.com
Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease - TipRanks
Belite Bio (NASDAQ:BLTE) Now Covered by Bank of America - Defense World
Belite Bio (NASDAQ:BLTE) Reaches New 1-Year HighStill a Buy? - MarketBeat
Belite Bio Surges on Breakthrough Eye Drug Hopes - TipRanks
Belite Bio stock hits all-time high at $170.35 - Investing.com
BofA Securities initiates coverage on Belite Bio stock with Buy rating - Investing.com
Avoiding Lag: Real-Time Signals in (BLTE) Movement - Stock Traders Daily
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
High Net Worth Advisory Group LLC Invests $259,000 in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
Assessing Belite Bio (BLTE) Valuation As Tinlarebant Progress And Pricing Plans Take Shape - Sahm
Dry Age Macular Degeneration Pipeline 2025: Key Companies, MOA, - openPR.com
Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock - Investing.com
Belite Bio, Inc (BLTE) Stock Analysis: A Biotech Gem With 19.70% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in BLTE Response - Stock Traders Daily
Belite Bio Reports Breakthrough Phase 3 Results for Stargardt Disease Treatment - MSN
Belite Bio stock hits all-time high at 169.88 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 169.88 USD - Investing.com
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target - Investing.com Nigeria
Belite Bio (NASDAQ:BLTE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target By Investing.com - Investing.com Canada
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
Behavioral Patterns of BLTE and Institutional Flows - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Shares Up 5.5%Should You Buy? - MarketBeat
Belite Bio stock hits all-time high at 163.25 USD - Investing.com
Belite Bio stock hits all-time high at 163.25 USD By Investing.com - Investing.com Australia
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Down 45.2% in December - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Belite Bio (NASDAQ:BLTE) Stock Rating Upgraded by Wall Street Zen - Defense World
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
The $100 ClubWere You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…? - RTTNews
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Sets New 1-Year HighHere's Why - MarketBeat
Can Belite Bio Inc (Common Stock) (D01) stock attract analyst upgradesMarket Movers & Expert Approved Trade Ideas - Улправда
Belite Bio, IncDepositary Receipt (BLTE) Price Target Increased by 21.98% to 116.02 - MSN
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Belite Bio (NASDAQ:BLTE) Sets New 52-Week High – Here’s What Happened - Defense World
Belite Bio Shares Surge After Landmark Phase 3 Success in Stargardt Disease - MSN
Belite Bio (NASDAQ:BLTE) Reaches New 52-Week HighShould You Buy? - MarketBeat
Belite Bio stock hits all-time high at 160.74 USD - Investing.com
Belite Bio stock hits all-time high at 160.74 USD By Investing.com - Investing.com Canada
Price-Driven Insight from (BLTE) for Rule-Based Strategy - news.stocktradersdaily.com
Belite Bio (NASDAQ:BLTE) Stock Price Down 5.9%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Clene (CLNN) and Costco (COST) - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Rating Increased to Outperform at Mizuho - MarketBeat
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):